Get the Stockscreener App
9.265
0.98%
0.085
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $9.265, with a volume of 3.16M.
It is up +0.98% in the last 24 hours and up +6.67% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.18
Open:
$9.2
24h Volume:
3.16M
Relative Volume:
0.21
Market Cap:
$10.61B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-2.9227
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+4.27%
1M Performance:
+6.67%
6M Performance:
-25.36%
1Y Performance:
-11.12%
1-Day Range:
$9.12
$9.295
1-Week Range:
$8.88
$9.34
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.27 | 10.61B | 14.33B | -3.79B | 1.84B | -3.17 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.33 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.35 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.23 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.44 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.00 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Andrew Smith Reports 2.90% Stake In Smarter Web Company As At June 13 Vs Prior Stake Of 10.39% - MarketScreener
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, - openPR.com
Viatris Inc’s Mixed Bag: Down -29.49% in 6 Months, Down 2.28% in 30 Days - investchronicle.com
3 Reasons to Avoid VTRS and 1 Stock to Buy Instead - Yahoo Finance
Viagra ‘Make Love Last’ wins Pharma Grand Prix after artfully working around Chinese ad regulations - Ad Age
ViatrisMAKE LOVE LAST59s - Ad Age
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released - Stock Titan
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris - sharewise
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Transcript : Viatris Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - marketscreener.com
Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral Recommendation - Nasdaq
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout - Insider Monkey
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga
Goldman Sachs Initiates Coverage on Viatris (VTRS) with Neutral Rating | VTRS Stock News - GuruFocus
Goldman Sachs starts Viatris stock coverage with neutral rating - Investing.com
Transcript : Viatris Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - marketscreener.com
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals And Viatris - Barchart.com
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS - TradingView
Class Action Lawsuit Filed: Viatris Inc. (VTRS)Join by June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
June 3, 2025 Deadline Approaching: Join Class Action Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris (VTRS) Reports Positive Phase 3 Trial Results for Night Driving Treatment - GuruFocus
Viatris sees positive top-line phase 3 results for night driving impairment asset - Seeking Alpha
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
June 3, 2025 Deadline: Join Class Action Lawsuit Against Viatris Inc. (VTRS)Contact Levi & Korsinsky - ACCESS Newswire
Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming DeadlinesVTRS - FinancialContent
Viatris reports success in phase 3 trial of night vision treatment MR-142 - Investing.com India
Viatris (VTRS) Reports Positive Results from LYNX-2 Trial for Eye Treatment | VTRS Stock News - GuruFocus
VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris - GlobeNewswire
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PR Newswire
Shareholders of Viatris Inc. (VTRS): Protect Your Rights Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Viatris Inc. (VTRS)June 3, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with ... - Bluefield Daily Telegraph
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRS - TradingView
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Lost Money on Viatris Inc. (VTRS)? Urged to Join Class Action Before June 3, 2025Contact Levi & Korsinsky - ACCESS Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider
Did You Lose Money on Viatris Inc. (VTRS)? Levi & Korsinsky Urges Investors to Act Before June 3, 2025 - Stockhouse
VTRS CLASS NOTICE: Viatris Inc. Investors may have been - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - marketscreener.com
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc.VTRS - Business Wire
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viatris Inc Stock (VTRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
41,112 |
0 |
60,441 |
| FINNEY ELISHA W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
37,832 |
| Le Goff Corinne | Chief Commercial Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
37,894 |
0 |
36,721 |
| Campbell Paul | See Remarks |
Mar 04 '25 |
Option Exercise |
0.00 |
207,325 |
0 |
328,250 |
| Campbell Paul | See Remarks |
Mar 03 '25 |
Option Exercise |
0.00 |
19,348 |
0 |
144,590 |
| Vivaldi Coelho Rogerio | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
21,691 |
0 |
21,691 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
96,431 |
0 |
266,825 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
146,700 |
0 |
221,178 |
| PARRISH MARK W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
140,395 |
| Lyons Dillon JoEllen | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
77,691 |
1.78%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):